Status:
UNKNOWN
Targeted and Staged Cyber Knife Combined With Interventional Therapy in the Treatment of MHCC
Lead Sponsor:
Chinese PLA General Hospital
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
Hepatocellular carcinoma is a highly malignant tumor that is progressing rapidly. Hepatic arterial embolization chemotherapy (TACE) is a common method for the treatment of unresectable of hepatocellul...
Eligibility Criteria
Inclusion
- Histologically or cytologically confirmed hepatocellular carcinoma
- No lymph node metastasis or distant metastasis
- Tumor diameter at least 10 cm
- Hepatic lesions are not suitable for surgical resection or the patient refuse to surgical treatment
- Eastern Clinical Oncology Group (ECOG)score is 0， 1or2
- No history of abdominal radiotherapy
- Inoperable and untransplantable,Child-pugh score A or B
- Normal liver volume exceeds 700 cm3
Exclusion
- Previous history of abdominal radiotherapy;
- The maximum diameter of tumor is less than 10cm;
- The liver Child is graded C;
- Contraindication for radiotherapy;
- Active gastrointestinal bleeding occurred within 2 weeks before enrollment
- Pregnancy
- Undergoing chemotherapy throughout the past six months
- Diffuse hepatocellular carcinoma
- Main portal vein tumor embolization
- Undergoing other simultaneous treatment
Key Trial Info
Start Date :
August 15 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 14 2020
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT03243916
Start Date
August 15 2017
End Date
July 14 2020
Last Update
August 9 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chinese PLA Gereral Hospital
Beijing, Beijing Municipality, China, 100000